NM26 – Talk Bio

Actionable Insights Powered by AI

Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics

Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics